Test Price
1,200 AED✅ Home Collection Available
NPM1 Gene Fragment Analysis in UAE | 1200 AED | PDPL Compliant
Executive Summary & Core Metrics
Clinical Excellence Directly to Your Doorstep
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
- Clinical Guidance: Complimentary Telephonic Post-Test Interpretation by DHA-licensed experts.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
NPM1 Gene Fragment Analysis is a high-resolution DNA test that detects mutations in the nucleophosmin (NPM1) gene, most commonly associated with acute myeloid leukemia (AML). It provides essential prognostic information and can be used to monitor minimal residual disease (MRD) after therapy.
| Feature | Our Test (DHA‑Regulated) | Closest Alternative (Standard Lab) |
|---|---|---|
| Methodology | Capillary Electrophoresis Fragment Analysis (FA‑CE) with automated allele calling | Conventional gel‑based or older Sanger sequencing (less sensitive) |
| Turnaround Time | 7–8 working days | 10–14 days |
| Sample Collection | Hospital Extraction Only – Accredited facility required; home phlebotomy disabled | In‑clinic draw only; limited transport conditions |
| Post‑Test Support | Free telephonic clinical guidance with DHA‑licensed consultant | Report only; minimal interpretation |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
“NPM1 mutation testing is a cornerstone of AML management. However, a negative result does not rule out other hematologic malignancies and must always be interpreted alongside clinical findings and additional biomarkers. Patients should discuss all results with their treating hematologist to ensure accurate integration into their care plan.”
Advisory on Medication and Clinical Management
⚠ Medication Safety Advisory
Do not discontinue or modify any prescribed medication (including hydroxyurea, targeted therapy, or supportive care) without consulting your supervising physician. This test provides genetic information; it does not replace ongoing clinical management.
Exclusion Criteria & Emergency Red Flags
- Active severe infection or uncontrolled sepsis – postpone elective testing.
- Recent platelet transfusion less than 24 hours before bone marrow collection may affect cellularity.
- Known severe bleeding diathesis – requires specialist clearance for invasive sampling.
- ER Red Flags: Sudden high fever (>38.3°C), uncontrolled bleeding, or acute confusion in a known leukemia patient warrants immediate emergency care, not a scheduled blood draw.
This test requires a valid physician’s prescription. For minors, consent must adhere to UAE Federal Decree-Law No. 4 of 2016 on Medical Liability. All data processed under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Patient FAQ & Clinical Guidance
1. What exactly is NPM1 Gene Fragment Analysis and why is it prescribed?
Direct Answer: NPM1 Gene Fragment Analysis detects specific mutations in the NPM1 gene using high‑sensitivity capillary electrophoresis, providing critical prognostic and treatment‑response information for acute myeloid leukemia patients.
It is primarily ordered by hematologists to confirm suspected AML with normal karyotype, stratify risk, and monitor residual disease after chemotherapy.
2. How is the sample collected, and does it require hospital visit?
Direct Answer: Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. A peripheral blood or bone marrow aspirate is obtained by qualified medical staff under sterile conditions.
A physician’s prescription is mandatory; all procedures follow DHA‑regulated infection control protocols.
3. Can an NPM1 mutation result influence my treatment decision?
Direct Answer: NPM1 mutation status directly impacts AML risk stratification and may guide the need for allogeneic stem cell transplantation or targeted maintenance therapy, making it a decisive factor in personalized care plans.
Always interpret results with your hematologist; a ‘negative’ does not exclude other actionable mutations.
UAE Regulatory & Data Privacy Adherence
Trust & Compliance
- All genetic data is processed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Consent and clinical safety procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Laboratory operations are ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139) and DHA‑licensed under facility number 1143.
- Secure storage and encrypted transmission of patient data ensures confidentiality and integrity.
Clinical & Logistical Metadata
| Test Name | NPM1 Gene Fragment Analysis |
| Price (AED) | 1,200 |
| Turnaround Time | 7–8 working days |
| Sample Type / Matrix | Peripheral whole blood or bone marrow aspirate (Hospital Extraction Only) |
| Methodology Used | Capillary Electrophoresis Fragment Analysis (FA‑CE) |
| ICD-10-CM Code | C92.0 |
| LOINC Code | 90078-7 |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE Corporate Lab Branding: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians